Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Limited history available
COAG Return on Equity (ROE) has fewer than three reported periods, so a trend chart would be misleading.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Hemab Therapeutics Holdings, Inc. Common Stock
Market Cap
$1.34B
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.34B
Return on Equity (ROE)
N/A
TTM Avg
44.32%
3Y Avg
153.88%
5Y Avg
43.56%
Market Cap
$1.32B
Return on Equity (ROE)
-210.13%
TTM Avg
-52.98%
3Y Avg
-43.11%
5Y Avg
1.89%
Market Cap
$1.40B
Return on Equity (ROE)
N/A
TTM Avg
-244.46%
3Y Avg
-323.47%
5Y Avg
-258.47%
Market Cap
$1.41B
Return on Equity (ROE)
N/A
TTM Avg
41.79%
3Y Avg
41.79%
5Y Avg
41.79%
Market Cap
$1.27B
Return on Equity (ROE)
N/A
TTM Avg
76.67%
3Y Avg
76.67%
5Y Avg
76.67%
Market Cap
$1.42B
Return on Equity (ROE)
9.00%
TTM Avg
8.29%
3Y Avg
7.90%
5Y Avg
8.39%
Market Cap
$1.41B
Return on Equity (ROE)
1849.06%
TTM Avg
-120.25%
3Y Avg
-118.83%
5Y Avg
-82.76%
Market Cap
$1.44B
Return on Equity (ROE)
-29.48%
TTM Avg
-5.20%
3Y Avg
-280.62%
5Y Avg
-280.62%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG) | $1.34B | N/A | N/A | N/A | N/A |
| Omeros Corporation (OMER)vs › | $1.34B | N/A | 44.32% | 153.88% | 43.56% |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.32B | -210.13% | -52.98% | -43.11% | 1.89% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | N/A | -244.46% | -323.47% | -258.47% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.41B | N/A | 41.79% | 41.79% | 41.79% |
| Kardigan, Inc. (KARD)vs › | $1.27B | N/A | 76.67% | 76.67% | 76.67% |
| The Pennant Group, Inc. (PNTG)vs › | $1.42B | 9.00% | 8.29% | 7.90% | 8.39% |
| AnaptysBio, Inc. (ANAB)vs › | $1.41B | 1849.06% | -120.25% | -118.83% | -82.76% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.44B | -29.48% | -5.20% | -280.62% | -280.62% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | N/A | 247.90% | 18.71% | 1.58% |
ROE
N/A
ROA
-32.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 36.18% |
